Caldose -1: A phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the efficacy and safety of IMU-838 for induction and maintenance therapy in moderate-to-severe ulcerative colitis
- Male or female 18 - 80 with UC
- Mayo score: >/= 2 Stool Freq; >/= 1 Rectal Bleeding; MES >/= 2
- Biological/Immunomodulator Failed or inadequate response/intolerance/dependent to steroids
- Induction, Extended Induction, Maintenance, and Open label phases in trial; Up to 10 years
- Oral Doses: 5mg vs 15mg vs 22.5mg vs placebo; 1:1:1:1. All receive drug in open label phase
If you are interested in participating in clinical studies, please send an email to email@example.com.